Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Adv Healthc Mater. 2019 Jan 3;8(4):e1801419. doi: 10.1002/adhm.201801419

Figure 4.

Figure 4.

A) Schematic for i.LN injection of MOG/Rapa MPs and analysis of their tolerogenic effects. B) Encapsulation of both MOG and rapamycin is required for the most potent tolerance. C) Tolerance induced by MOG/Rapa MPs is antigen specific. D) MOG/Rapa increases TREG in treated and untreated LNs. E) MOG/Rapa MPs reduce T cell proliferation in the CNS of mice induced with EAE. Adapted from [100].